Artificial Intelligence (AI) In Biopharmaceuticals Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Artificial Intelligence (AI) In Biopharmaceuticals Market Revenue Growth Supported By A CAGR Of 8.77% Through 2030
The market for artificial intelligence (AI) in biopharmaceuticals has experienced exponential expansion in recent years. Projected to increase from $2.1 billion in 2025 to $2.79 billion in 2026, this growth represents a compound annual growth rate (CAGR) of 33.0%. Factors driving progress during the historical period include the early adoption of AI within pharmaceutical research, enhanced computational capabilities, heightened investment in biopharmaceutical research and development, the integration of omics data, and the proliferation of cloud-based data storage solutions.
The artificial intelligence (AI) sector within biopharmaceuticals is poised for rapid expansion over the coming years. By 2030, it is projected to reach a valuation of $8.77 billion, reflecting a compound annual growth rate (CAGR) of 33.1%. This anticipated growth during the forecast period is fueled by several key factors, such as progress in machine learning algorithms, broader deployment of AI-powered laboratory tools, a greater reliance on predictive analytics, a surge in collaborative initiatives between AI firms and biopharma companies, and government support for AI-driven healthcare solutions. Notable developments shaping this period include AI-facilitated drug discovery, the application of predictive analytics to clinical trials, lab automation, the use of real-world data, and customized approaches to treatment optimization.
Download A Free Sample Report For Comprehensive Market Insights:
Artificial Intelligence (AI) In Biopharmaceuticals Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing occurrence of chronic illnesses is set to boost the expansion of artificial intelligence (AI) within the biopharmaceuticals sector in the coming years. Chronic diseases, which are persistent conditions that typically advance gradually and can last for years or a lifetime, stem from factors such as lifestyle choices, an aging demographic, genetic tendencies, and environmental influences. AI’s role in biopharmaceuticals has become crucial for managing these conditions because it processes extensive and varied data sets, uncovers trends, and tailors treatment strategies to individuals. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal agency, reported that about 194 million American adults—equivalent to 76.4%—had at least one chronic condition in 2023. This prevalence varied by age, affecting 59.5% of younger adults, 78.4% of those in midlife, and 93.0% of older individuals. Consequently, the rising prevalence of chronic diseases is fueling the growth of artificial intelligence (AI) in the biopharmaceuticals market.
Artificial Intelligence (AI) In Biopharmaceuticals Market Segment Performance And Strategic Opportunities
The artificial intelligence (ai) in biopharmaceuticals market covered in this report is segmented –
1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Drug Discovery, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes
Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services
Artificial Intelligence (AI) In Biopharmaceuticals Market Trends Reshaping Industry Growth
Key industry players in the artificial intelligence (AI) sector for biopharmaceuticals are concentrating on creating cutting-edge innovations, including AI-driven solutions for target and lead identification, which accelerate drug discovery and enable precision medicine, thereby transforming life sciences organizations. These drug discovery and precision medicine solutions incorporate a range of novel methods for developing new medications and customizing treatments for individual patients. For example, in May 2023, Google LLC, a U.S.-based cloud computing provider, introduced two new AI-powered tools—the target and lead identification suites—designed to assist researchers in predicting and comprehending protein structures, a critical component of drug development. Furthermore, these tools facilitate the ingestion, storage, analysis, and sharing of extensive genomic data, which is essential for precision medicine, and they aim to expedite the drug discovery process, lower expenses, and accelerate the availability of new therapies. Through efficient data management, precise protein structure predictions, and advanced genomic analysis, these innovations are intended to transform drug development workflows and enhance patient outcomes.
Artificial Intelligence (AI) In Biopharmaceuticals Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the artificial intelligence (ai) in biopharmaceuticals market are Exscientia Limited, DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.
Access The Complete Artificial Intelligence (AI) In Biopharmaceuticals Market Report:
Artificial Intelligence (AI) In Biopharmaceuticals Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in biopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
